Loading clinical trials...
Loading clinical trials...
Multicentre Study to Assess Persistence of Antibodies Against Hepatitis B and Immune Response to a Hepatitis B Challenge Dose in Healthy Children 7 to 9 Years Old Previously Vaccinated With 4 Doses of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine
Conditions
Interventions
hepatitis B vaccine
Locations
42
Germany
GSK Investigational Site
Ettenheim, Baden-Wurttemberg, Germany
GSK Investigational Site
Kehl, Baden-Wurttemberg, Germany
GSK Investigational Site
Oberkirch, Baden-Wurttemberg, Germany
GSK Investigational Site
Offenburg, Baden-Wurttemberg, Germany
GSK Investigational Site
Aichach, Bavaria, Germany
GSK Investigational Site
Bobingen, Bavaria, Germany
Start Date
July 1, 2006
Completion Date
December 1, 2006
Last Updated
October 12, 2016
NCT07024641
NCT06671093
NCT07275554
NCT03826433
NCT06885710
NCT06947499
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions